Systemic treatment with cpg-b after sublethal rickettsial infection induces mouse death through indoleamine 2,3-dioxygenase (ido)

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Xin, Lijun ^a   Shelite, Thomas R ^a   Gong, Bin ^a   Mendell, Nicole L ^a   Soong, Lynn ^a   Fang, Rong ^a   Walker, David H ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE B; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROGRAMMED DEATH 1 RECEPTOR; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CHEMOKINE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; CYTOKINE; OLIGODEOXYRIBONUCLEOTIDE; PDCD1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL LOAD; CELLULAR IMMUNITY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; HISTOPATHOLOGY; LETHAL DOSE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PLASMACYTOID DENDRITIC CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RICKETTSIACEAE INFECTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECT; ENZYMOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RICKETTSIA; T LYMPHOCYTE;

BACTERIA (MICROORGANISMS); MUS;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CHEMOKINES; CYTOKINES; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OLIGODEOXYRIBONUCLEOTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; RICKETTSIACEAE INFECTIONS; RICKETTSIEAE; T-LYMPHOCYTES;

EID: 84859042546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034062     Document Type: Article

References (47)

1. Krieg AM, (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760.
2. Klinman DM, (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4: 249-258.
3. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, et al. (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160: 3627-3630.
4. Krieg AM, Love-Homan L, Yi AK, Harty JT, (1998) CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 161: 2428-2434.
5. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM, (1999) Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 162: 2291-2298.
6. Klinman DM, Conover J, Coban C, (1999) Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 67: 5658-5663.
7. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, et al. (1999) Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163: 1552-1561.
8. Serebrisky D, Teper AA, Huang CK, Lee SY, Zhang TF, et al. (2000) CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol 165: 5906-5912.
9. Krieg AM, (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117: 1184-1194.
10. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM, (2011) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10: 499-511.
11. Munn DH, Mellor AL, (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154.
12. Johnson BA 3rd, Baban B, Mellor AL, (2009) Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 1: 645-661.
13. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, et al. (2004) Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 114: 270-279.
14. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, et al. (2005) Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175: 5601-5605.
15. Baban B, Chandler PR, Johnson BA 3rd, Huang L, Li M, et al. (2011) Physiologic control of IDO competence in splenic dendritic cells. J Immunol 187: 2329-2335.
16. Wingender G, Garbi N, Schumak B, Jungerkes F, Endl E, et al. (2006) Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 36: 12-20.
17. Feng HM, Wen J, Walker DH, (1993) Rickettsia australis infection: a murine model of a highly invasive vasculopathic rickettsiosis. Am J Pathol 142: 1471-1482.
18. Feng H, Popov VL, Yuoh G, Walker DH, (1997) Role of T lymphocyte subsets in immunity to spotted fever group Rickettsiae. J Immunol 158: 5314-5320.
19. Walker DH, Olano JP, Feng HM, (2001) Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. Infect Immun 69: 1841-1846.
20. Takikawa O, Kuroiwa T, Yamazaki F, Kido R, (1988) Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263: 2041-2048.
21. Labruna MB, Whitworth T, Horta MC, Bouyer DH, McBride JW, et al. (2004) Rickettsia species infecting Amblyomma cooperi ticks from an area in the state of Sao Paulo, Brazil, where Brazilian spotted fever is endemic. J Clin Microbiol 42: 90-98.
22. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, et al. (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9: 1069-1077.
23. Hayashi T, Mo JH, Gong X, Rossetto C, Jang A, et al. (2007) 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci U S A 104: 18619-18624.
24. Feng HM, Walker DH, (1993) Interferon-gamma and tumor necrosis factor-alpha exert their antirickettsial effect via induction of synthesis of nitric oxide. Am J Pathol 143: 1016-1023.
25. Walker DH, Popov VL, Crocquet-Valdes PA, Welsh CJ, Feng HM, (1997) Cytokine-induced, nitric oxide-dependent, intracellular antirickettsial activity of mouse endothelial cells. Lab Invest 76: 129-138.
26. Ito S, Ishii KJ, Ihata A, Klinman DM, (2005) Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes. Infect Immun 73: 3803-3805.
27. Jordan JM, Woods ME, Olano J, Walker DH, (2008) The absence of Toll-like receptor 4 signaling in C3H/HeJ mice predisposes them to overwhelming rickettsial infection and decreased protective Th1 responses. Infect Immun 76: 3717-3724.
28. Sasai M, Linehan MM, Iwasaki A, (2010) Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329: 1530-1534.
29. Minton K, (2010) Two for the price of one. Nat Rev Immunol 10: 746.
30. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, et al. (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117: 2570-2582.
31. Fang R, Ismail N, Shelite T, Walker DH, (2009) CD4+ CD25+ Foxp3- T-regulatory cells produce both gamma interferon and interleukin-10 during acute severe murine spotted fever rickettsiosis. Infect Immun 77: 3838-3849.
32. Scumpia PO, Delano MJ, Kelly KM, O'Malley KA, Efron PA, et al. (2006) Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol 177: 7943-7949.
33. Ertelt JM, Rowe JH, Mysz MA, Singh C, Roychowdhury M, et al. (2011) Foxp3+ regulatory T cells impede the priming of protective CD8+ T cells. J Immunol 187: 2569-2577.
34. Mellor AL, Munn DH, (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774.
35. Xu H, Zhang GX, Ciric B, Rostami A, (2008) IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett 121: 1-6.
36. Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, et al. (2009) The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 182: 7509-7517.
37. Jung ID, Lee MG, Chang JH, Lee JS, Jeong YI, et al. (2009) Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J Immunol 182: 3146-3154.
38. Huttunen R, Syrjanen J, Aittoniemi J, Oja SS, Raitala A, et al. (2010) High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 33: 149-154.
39. Muller AJ, Mandik-Nayak L, Prendergast GC, (2010) Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy 2: 293-297.
40. Cowdery JS, Chace JH, Yi AK, Krieg AM, (1996) Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 156: 4570-4575.
41. Sparwasser T, Miethke T, Lipford G, Borschert K, Hacker H, et al. (1997) Bacterial DNA causes septic shock. Nature 386: 336-337.
42. Yi AK, Yoon JG, Hong SC, Redford TW, Krieg AM, (2001) Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. Int Immunol 13: 1391-1404.
43. Navarini AA, Lang KS, Verschoor A, Recher M, Zinkernagel AS, et al. (2009) Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. Proc Natl Acad Sci U S A 106: 7107-7112.
44. Bogdan C, (2001) Nitric oxide and the immune response. Nat Immunol 2: 907-916.
45. Krieg AM, (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484.
46. Vollmer J, Krieg AM, (2009) Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61: 195-204.
47. Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, et al. (2009) Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PloS One 4: e8368.